Slide 1: Orion Full Year 2022 results
Orion Full Year 2022 results 9 February 2023
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Orion's eventful year laid foundation for future growth
Orion’s eventful year laid foundation for future growth Bayer updated estimate on Acquisition of animal health Nubeqa®’s peak sales potential company VMD A global development and Research focus on commercialisation agreement oncology and pain with MSD on ODM-208 New organizational structure and FDA
Slide 4: Exceptionally high net sales and operating profit
Exceptionally high net sales and operating profit The impact of ODM-208 upfront payment shown in all key figures Cash flow from Operating profit Net sales Operating profit operating activities margin per share MEUR MEUR EUR 1,341 440 33% 3.09 (1,041) +29% (243) +81% (23%) (1.53) +101% w/o ODM-208 up
Slide 5: Net sales bridge FY2021 to FY2022
Net sales bridge FY2021 to FY2022 1 Simdax® & Dexdor® 5 Animal Health and Fermion & Contract Manufacturing 2 Nubeqa® (product sales & royalty) 6 Exchange rates 3 Easyhaler® product portfolio 7 Royalties & milestones (without Nubeqa® royalties) 4 Other Proprietary and Specialty Products 5 9 February
Slide 6: Operating profit bridge FY2021 to FY2022
Operating profit bridge FY2021 to FY2022 The impact of fx rates varied strongly during the year - negative in Q1 and Q4, positive in Q2 and Q3 1 Product & service sales without sales margin and 4 Milestones & royalties product mix change and exchange rate effect 2 Product sales margin and product mi
Slide 7: Growth in product sales
Growth in product sales +66% 700 644 Sales split +4% 600 1% 521 503 500 5% 7% 416 388 w/o ODM-208 upfront (+7%) 400 39% MEUR 300 200 +35% -8% 48% 99 100 73 75 69 2 8 0 Specialty Products Specialty Proprietary Animal Health Fermion & Other* Proprietary Products Products Products Contract Animal Healt
Slide 8: TOP 10 products in 2022
TOP 10 products in 2022 EUR vs. Product or product portfolio million 1−12/2021 1. Easyhaler® product portfolio 130 +11% 2. Stalevo®, Comtess®, Comtan® 100 +5% 3. Nubeqa® 88 +122% 4. Simdax® 43 -25% 5. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 36 -6% 6. Divina® series 28 +19% 7. Burana® 27 +13% 8
Slide 9: Proprietary Products
Proprietary Products 300 • The impact of ODM-208 upfront payment 265 shown in ‘Others’ 250 • Nubeqa® driving the growth • Fine year for Easyhaler® product portfolio 200 • Timing of partner deliveries explaining the +11% +5% growth in Parkinson’s franchise MEUR 150 130 117 +122% • Expected decline fo
Slide 10: Strong growth for Nubeqa sales booked by Orion
Strong growth for Nubeqa® sales* booked by Orion 40 • Orion is entitled to receive annually tiered royalties on global darolutamide sales. The average annual 35 royalty rate is initially approximately 20% including 30 product sales to Bayer. At first, the average annual royalty rate will be slightly
Slide 11: Specialty Products
Specialty Products 450 350 +1% +4% Sales split by geographic 400 380 384 300 278 289 areas 350 250 300 200 15% MEUR 250 MEUR 150 -2% +13% 200 +11% 15% 100 76 76 81 80 76 150 137 67 123 55% 50 100 0 15% 50 0 Generic Self-care products prescription drugs Finland Scandinavia 1–12/2021 1–12/2022 1–12/20
Slide 12: Overview of the Finnish Pharmaceutical Market
Overview of the Finnish Pharmaceutical Market Price decline of reference priced prescription drugs offset by strong volume growth 1-12/2022 Market Orion Orion’s Orion’s sales split Finland’s share of Orion EUR million market share Group’s total net sales* Total sales of human 3,081 335 33% 33% 11% 2
Slide 13: Animal Health and Fermion & Contract Manufacturing
Animal Health and Fermion & Contract Manufacturing • Animal Health growth due to Animal Health Fermion acquisition of animal health 120 120 +35% company VMD in June 99 -8% 100 100 • Sedatives remain the largest product group in Animal Health 80 73 36 80 75 69 • The decline in Fermion’s reported exte
Slide 14: New organisational structure as of 1 January 2023
New organisational structure as of 1 January 2023 Main changes – comparable net sales from 2022 for new business divisions will be published later Fermion & Contract Proprietary Products Specialty Products Animal Health Manufacturing Generics & Innovative Medicines Branded Products Animal Health Fer
Slide 15: Key clinical development pipeline
Key clinical development pipeline Project/compound Indication PHASE I PHASE II PHASE III REGISTRATION ARASENS / darolutamide 1 Prostate cancer (mHSPC) ARANOTE / darolutamide 1 Prostate cancer (mHSPC) ODM-208 2 Prostate cancer (mCRPC) ODM-105 / tasipimidine Psychiatric disorders ODM-111 (NaV 1.8 bloc
Slide 16: Orion's Sustainability Agenda and indicators 2022
Orion’s Sustainability Agenda and indicators 2022 Patient safety as a top priority Active work for a better environment Care for well-being professionals Ethics at the core of our business Customer GxP* audits Greenhouse gas Energy savings Injury rate ABC* training, no. complaints by Orion emissions
Slide 17: Outlook for 2023
Outlook for 2023 Net sales Orion estimates that net sales in 2023 will be slightly higher than in 2022 without the EUR 228 million impact from ODM-208 upfront payment (net sales in 2022 without the impact of the ODM-208 upfront payment were EUR 1,113 million). Operating profit Operating profit is es
Slide 18: Basis for the outlook – key contributors
Basis for the outlook – key contributors Net sales Operating profit Nubeqa® Generic Nubeqa® Operating costs Animal Health competition COGS** Milestones* Milestones* Russia Simdax® and other declining Easyhaler® Pricing products pressure * Excluding ODM-208 upfront payment * Excluding ODM-208 upfront
Slide 19: Upcoming events
Upcoming events AGM planned to be held 22/3/2023 Interim Report 1-3/2023 27/4/2023 Half-Year Financial Report 17/7/2023 Interim Report 1-9/2023 26/10/202 19 9 February 2023 © Orion Corporation
Slide 20: Save the date: Orion Capital Markets Day
Save the date Orion Capital Markets Day on 25 May 2023 20 9 February 2023 © Orion Corporation